Literature DB >> 10761822

Choosing antipsychotic maintenance therapy--a naturalistic study.

R Tavcar1, M Z Dernovsek, V Zvan.   

Abstract

Antipsychotic maintenance treatment is essential for preventing relapses of schizophrenia, but the variety of available antipsychotics may complicate the choice of drug. The aim of our naturalistic one-year follow-up study was to find out the factors predicting the choice of antipsychotics in discharged patients with schizophrenia or schizoaffective disorder and the predictors of one-year rehospitalization. The patients were receiving oral or depot classical antipsychotics or atypical agents clozapine or risperidone. Symptoms were assessed with Present State Examination. Included were 447 patients (202 males and 245 females) with a mean age of 39.1 years and 5.9 previous hospitalizations. The majority of patients (n = 322) were receiving depot antipsychotics and 43 were prescribed atypical agents. Two predictive models were built using the logistic regression analysis. Previously prescribed depot antipsychotics were positively related to further depot use, while patients who left the hospital against medical advice and those with slowness of speech at admission were less likely to receive depot drugs. On the other hand, previously used atypical antipsychotics and longer hospitalization predicted further use of atypical agents while patients discharged to community care facilities or nursing homes and those with more frequent previous hospitalizations were less likely to receive atypical agents. The Cox survival analysis showed the following one-year rehospitalization risk factors: diagnosis of schizoaffective disorder, frequent previous hospitalizations, inappropriate behavior, and oral classical antipsychotics versus depot or atypical agents. This study may yield some insight into the decision-making process in everyday clinical work regarding the choice of antipsychotic maintenance medication and its influence on rehospitalization rate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761822     DOI: 10.1055/s-2000-7969

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; Stefan Leucht; Mark Olfson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

2.  The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.

Authors:  David P Walling; Howard A Hassman; Lourdes Anta; Lourdes Ochoa; Ignacio Ayani; Javier Martínez; Ibon Gutierro
Journal:  Drug Des Devel Ther       Date:  2021-10-15       Impact factor: 4.162

Review 3.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

4.  Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study.

Authors:  Hamid-Reza Ahmadkhaniha; Shahab Bani-Hashem; Masoud Ahmadzad-Asl
Journal:  Iran J Psychiatry Behav Sci       Date:  2014
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.